Faratian D, Bartlett J
Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh, UK.
Histopathology. 2008 Jan;52(1):91-8. doi: 10.1111/j.1365-2559.2007.02896.x.
The published literature is awash with examples of new tissue biomarkers promising to predict responses to therapy in breast cancer patients. However, few, if any, of these progress from the laboratory to the clinic. In this review we discuss some of the reasons for this, illustrating our discussion with a selection of biomarkers which are in development and which may be candidates for clinical application within the next few years (topoisomerase II alpha, epidermal growth factor receptor, AKT, phosphatase and tensin homologue). In particular, we explore how our ever increasing knowledge of molecular and pathway biology is facilitating hypothesis-driven biomarker discovery, and the statistical considerations which need to be addressed in order to validate new candidate biomarkers adequately.
已发表的文献中充斥着各种新的组织生物标志物的例子，这些标志物有望预测乳腺癌患者对治疗的反应。然而，其中很少有（如果有的话）能从实验室进入临床应用。在本综述中，我们讨论了造成这种情况的一些原因，并通过选择一些正在研发且可能在未来几年内成为临床应用候选物的生物标志物（拓扑异构酶IIα、表皮生长因子受体、AKT、磷酸酶和张力蛋白同源物）来说明我们的讨论。特别是，我们探讨了我们对分子和信号通路生物学不断增加的了解如何促进基于假设的生物标志物发现，以及为充分验证新的候选生物标志物而需要考虑的统计学因素。
